These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8020528)

  • 1. Study on the absorption of vinpocetine and apovincaminic acid.
    Pudleiner P; Vereczkey L
    Eur J Drug Metab Pharmacokinet; 1993; 18(4):317-21. PubMed ID: 8020528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of apovincaminic acid in dogs.
    Vereczkey L; Pudleiner P
    Pol J Pharmacol Pharm; 1987; 39(2):161-5. PubMed ID: 3432163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid.
    Miskolczi P; Vereczkey L; Szalay L; Göndöc C
    Eur J Clin Pharmacol; 1987; 33(2):185-9. PubMed ID: 3691609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans.
    Miskolczi P; Kozma K; Polgár M; Vereczkey L
    Eur J Drug Metab Pharmacokinet; 1990; 15(1):1-5. PubMed ID: 2384112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and metabolic studies of vinpocetine on dogs. II. Metabolism.
    Szeleczky G; Vereczkey L
    Pol J Pharmacol Pharm; 1986; 38(3):269-75. PubMed ID: 3774625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omeprazole does not change the oral bioavailability or pharmacokinetics of vinpocetine in rats.
    Sozański T; Magdalan J; Trocha M; Szumny A; Merwid-Ląd A; Słupski W; Karaźniewicz-Łada M; Kiełbowicz G; Ksiądzyna D; Szeląg A
    Pharmacol Rep; 2011; 63(5):1258-63. PubMed ID: 22180371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic metabolism of vinpocetine in the rat.
    Vereczkey L; Szentirmay Z; Szporny L
    Arzneimittelforschung; 1979; 29(6):953-6. PubMed ID: 582790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinpocetine pharmacokinetics in elderly subjects.
    Grandt R; Beitinger H; Schaltenbrand R; Braun W
    Arzneimittelforschung; 1989 Dec; 39(12):1599-602. PubMed ID: 2624613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of apovincaminic acid in serum by means of high-performance liquid chromatography.
    Kraus G; Schulz HU; Lohmann A
    J Chromatogr; 1992 Jan; 573(2):323-7. PubMed ID: 1601968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of apovincaminic acid in human plasma by high-performance liquid chromatography.
    Maya MT; Pais JP; Araújo HM; Morais JA
    J Pharm Biomed Anal; 1996 Mar; 14(5):617-22. PubMed ID: 8738192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Human positron emission tomography with oral 11C-vinpocetine].
    Vas A; Christer H; Sóvágó J; Johan S; Cselényi Z; Kiss B; Kárpáti E; Lars F; Gulyás B
    Orv Hetil; 2003 Nov; 144(46):2271-6. PubMed ID: 14702922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of apovincaminic acid in biological samples by high-performance liquid chromatography.
    Kozma M; Pudleiner P; Vereczkey L
    J Chromatogr; 1982 May; 241(1):177-82. PubMed ID: 7107794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral circulatory and cardiac effects of vinpocetine and its metabolite, apovincaminic acid, in anesthetized dogs.
    Imamoto T; Tanabe M; Shimamoto N; Kawazoe K; Hirata M
    Arzneimittelforschung; 1984; 34(2):161-9. PubMed ID: 6539108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of apovincaminic acid in human plasma by high-performance liquid chromatography using solid-phase extraction and ultraviolet detection.
    Chen J; Cai J; Tao W; Mei N; Cao S; Jiang X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jan; 830(2):201-6. PubMed ID: 16321580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine.
    Gulyás B; Halldin C; Sóvágó J; Sandell J; Cselényi Z; Vas A; Kiss B; Kárpáti E; Farde L
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1031-8. PubMed ID: 12173017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the possible influence of the absorption of vinpocetine with concomitant application of magnesium-aluminium-hydroxide gel.
    Lohmann A; Grobara P; Dingler E
    Arzneimittelforschung; 1991 Nov; 41(11):1164-7. PubMed ID: 1810262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics and disposition of vinpocetine in rats].
    Yao JH; Su CY; Chu XY
    Yao Xue Xue Bao; 1994; 29(2):81-5. PubMed ID: 8042515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter.
    Vlase L; Bodiu B; Leucuta SE
    Arzneimittelforschung; 2005; 55(11):664-8. PubMed ID: 16366040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of vinpocetine and apovincaminic acid in patients with impaired renal function.
    Miskolczi P; Vereczkey L; Szalay L; Göndöcs CS
    Eur J Drug Metab Pharmacokinet; 1984; 9(2):169-75. PubMed ID: 6745306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of pharmacokinetic interaction between vinpocetine and oxazepam.
    Storm G; Oosterhuis B; Sollie FA; Visscher HW; Sommer W; Beitinger H; Jonkman JH
    Br J Clin Pharmacol; 1994 Aug; 38(2):143-6. PubMed ID: 7981015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.